Duchenne Muscular Dystrophy and neuromuscular disease
Antisense Therapeutics Limited focuses its clinical research activity on Duchenne Muscular Dystrophy, with attention to the functional limitations experienced by non-ambulant participants and the preservation of upper limb muscle function. The sponsor’s work is centred on the clinical burden of progressive muscle weakness and loss of motor ability in this rare neuromuscular condition.
- Non-ambulant DMD
- Upper limb function
- Muscle performance
Its research interest includes outcomes relevant to day-to-day physical function in advanced Duchenne Muscular Dystrophy, particularly measures used to track changes in limb strength and mobility-related capability.
Antisense therapy and molecular treatment approaches
The sponsor is active in antisense-based therapeutics, reflecting a therapeutic focus on molecular intervention in genetic disease. Its clinical programme is associated with ATL1102 and the investigation of treatment effects in neuromuscular disorders.
- Antisense oligonucleotide research
- ATL1102
- Genetic disease therapy
This area of interest links molecular pharmacology with therapeutic development for inherited muscle disease, with emphasis on clinical relevance in Duchenne Muscular Dystrophy.
Safety, tolerability, and pharmacokinetics
Clinical research funded by the sponsor also addresses safety and tolerability in long-term treatment use, alongside pharmacokinetic characterisation of a subcutaneously administered therapy. These areas are central to understanding how the investigational treatment behaves in participants with Duchenne Muscular Dystrophy.
- Safety monitoring
- Tolerability assessment
- Pharmacokinetic profile
The sponsor’s interest extends to sustained treatment exposure in a rare disease setting, with clinical evaluation in non-ambulant participants receiving ongoing therapy.
Clinical regulation and trial conduct
As a pharmaceutical sponsor with Clinical and Regulatory Affairs activity, Antisense Therapeutics Limited is involved in the clinical development and oversight of research in Australia. Its current trial activity is concentrated in a single-country setting with a collaborating research site supporting the study of Duchenne Muscular Dystrophy.
- Clinical development
- Regulatory affairs
- Australia-based research
The sponsor’s research landscape is defined by a focused therapeutic programme in rare disease neuromuscular medicine, with clinical evaluation directed toward functional outcomes and treatment acceptability.
